AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$ZBH

Thornal Kevin R sold $529K of ZBH

Thornal Kevin R (Grp Pres-Global Business) sold 5,691 shares of ZIMMER BIOMET HOLDINGS, INC. (ZBH) at $92.95 ($0.53M total) on 2026-09-11.

Original reporting
SEC EDGAR · Thornal Kevin R
Published Sep 15, 2026, 8:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ZBH
Bearish
high confidence
Mentioned
$ZBH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZBHBearishLow
01

Why it matters

The insider's complete exit could be interpreted as a lack of confidence, but the modest amount limits market reaction.

02

Market read

Minor insider sale; unlikely to affect ZBH price materially.

03

What to watch

Potential tax‑loss harvesting or personal liquidity needs could drive the transaction.

Relevance 5/10Novelty 3/10Timing: filed today

Background

SEC Form 4 filings disclose insider transactions; traders monitor them for signals.

Company-level read

Ticker impact

$ZBHBearishHigh confidence
Context

Officer Thornal Kevin R sold 5,691 shares of ZBH for $528,978 on 2026-09-11.

Expected impact

Minimal short‑term pressure; unlikely to move the stock materially.

Evidence & confidence

The sale size (~$0.5 M) is small relative to market cap; insider exits can signal concern but the amount is not material.

Market effects

Sector

Limited; does not affect broader orthopedic device sector.

Regional

None; confined to ZBH shareholders.

Global

Low; no cross‑market ripple.

Counterpoint

What could challenge this read

The sale may be routine portfolio rebalancing rather than a negative signal.

Key entities

  • Company
    Zimmer Biomet Holdings, Inc.

    Medical device manufacturer listed on NYSE under ZBH.

  • Insider
    Thornal Kevin R

    Group President – Global Business, officer of ZBH.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ZBH insider trading history →

Related articles

AUG 14
$ZBHMed

Are Wall Street Analysts Bullish on Zimmer Biomet Stock?

Zimmer Biomet (ZBH) reported Q2 results on Aug. 5, with adjusted EPS of $2.07 vs $2.01 expected and revenue of $2.2B vs $2.1B forecast. The company guided full-year adjusted EPS to $8.47-$8.59. Analysts covering ZBH have a Hold consensus, with a mean price target of $104.67 and a Street-high of $125.

barchart.com4 min
AUG 7
$ZBHMedAI 8/10

Zimmer Biomet Holdings, Inc. Q2 2026 Earnings Call Summary

Zimmer Biomet reported Q2 2026 organic constant-currency revenue growth of 4%, led by a 4.6% U.S. increase and 3.1% international growth. Management raised full-year organic guidance to 2.25%-3.25% and adjusted EPS to $8.47-$8.59, including $1B planned 2026 share repurchases. China revenue fell 20%.

yahoo.com7 min
AUG 5
$ZBHHighAI 9/10

ZBH's Q2 Earnings Beat, '26 View Raised, Stock Up in Pre-Market

Zimmer Biomet (ZBH) reported Q2 2026 adjusted EPS of $2.07, above the $2.01 consensus, and net sales of $2.18B, above the $2.13B estimate. GAAP EPS was $1.03. The company raised 2026 guidance, including revenue growth to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59. Shares rose 1.4% pre-market.

zacks.com7 min